- FDA Approves Ajovy (fremanezumab-vfrm) for Preventive Treatment of Migraine
- FDA Approves Xelpros (latanoprost ophthalmic emulsion) to Treat Open-angle Glaucoma or Ocular Hypertension
- FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA)
- FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia
- FDA Approves Cassipa (buprenorphine and naloxone) Sublingual Film as Maintenance Treatment for Opioid Dependence
- ITF Pharma Announces FDA Approval of Tiglutik (riluzole) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
- FDA Approves Merck’s Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Appropriate Patients
- FDA Approves Merck’s Pifeltro (doravirine) for the Treatment of HIV-1 in Appropriate Patients
- Bayer Receives FDA Approval for Jivi (antihemophilic factor (recombinant), PEGylated-aucl) for Prophylactic Treatment of Hemophilia A
- Tetraphase Pharmaceuticals Announces FDA Approval of Xerava (eravacycline) for Complicated Intra-Abdominal Infections (cIAI)
- FDA Approves Imbruvica (ibrutinib) Plus Rituximab for Patients with Waldenström’s Macroglobulinemia
- Ortho Dermatologics Receives FDA Approval for Altreno (tretinoin 0.05%) Lotion For Acne
- FDA Approves Takhzyro (lanadelumab-flyo) for Hereditary Angioedema
- FDA Approves Inveltys (loteprednol etabonate) for Post-Operative Inflammation and Pain Following Ocular Surgery
- FDA Approves Oxervate (cenegermin) for Neurotrophic Keratitis